Ventricular tachycardia are difficult to understand. it is classified in to two types. 1. VT in structurally normal heart, 2. VT in heart with structural diseases. I have tried to simplify the VT in structurally normal heart, which may be helpful to many students and learners.
Idiopathic VT refers to VT occurring in structurally normal hearts in the absence of myocardial scarring. Classification of monomorphic idiopathic VT includes outflow tract VT, fascicular VT, papillary muscle VT,annular VT, and miscellaneous (VT from the body of the RV and crux of
the heart). It is commonly seen in young patients and usually has a benign course. The 12-lead lectrocardiogram is critical in distinguishing the specific form and locations of idiopathic VT. Treatment options include medical therapy specific to the underlying mechanism of VT or catheter
ablation.
Idiopathic VT refers to VT occurring in structurally normal hearts in the absence of myocardial scarring. Classification of monomorphic idiopathic VT includes outflow tract VT, fascicular VT, papillary muscle VT,annular VT, and miscellaneous (VT from the body of the RV and crux of
the heart). It is commonly seen in young patients and usually has a benign course. The 12-lead lectrocardiogram is critical in distinguishing the specific form and locations of idiopathic VT. Treatment options include medical therapy specific to the underlying mechanism of VT or catheter
ablation.
preop TEE assessment of atrial septal defect is very important for making decision for device closure, properly assessed adequate rims of ASD will reduce risk of device embolization to almost nil.
preop TEE assessment of atrial septal defect is very important for making decision for device closure, properly assessed adequate rims of ASD will reduce risk of device embolization to almost nil.
Its crucial to diagnose arrythmias quickly and treat it promptly.
Here i have made small attempt to diagnose tachyarrythmias briefly and proceeds with its immediate managenent..
Ventricular tachycardia (VT) is a broad complex tachycardia originating from a ventricular ectopic focus. It is defined as three or more ventricular extrasystoles in succession at a rate of more than 120 beats per minute (bpm). Accelerated idioventricular rhythm refers to ventricular rhythms with rates of 100-120 bpm
Was Sie schon immer über das EKG wissen wollten…www.fokus-ekg.deCharite
A presentation about ECG-basics (left ventricular hypertrophy, relevance of lead V1 for making the correct diagnosis (presentation in German). For further ECGs (with free download) see: www.fokus-ekg.de.
differentiating between supraventicular tachycardia and ventricular tachycardia in wide complex rhythm is always confusing and management is totally different. correct diagnosis will make dramatic difference in patient management.
Case scenario of a patient with idiopathic ventricular Tachycardia (VT), followed by a topic review including diagnosis and management guidelines. It is defined as Monomorphic VT in patients without any structural heart disease or coronary disease”. Classified on the basis of site of origin broadly into three different categories i.e Outflow Tract VT, Annular VT, Fascicular VT
Acute pulmonary embolism - risk stratification and managementPrithvi Puwar
what is the guideline recommendation and ideal to be done in management of acute pulmonary embolism. the presentation includes risk stratification, recommendation and approach to investigations (guidelines based) and management options with evidence.
PRN Medications; its justified use: by Dr Prithvi PuwarPrithvi Puwar
The presentation is mentioning the details of PRN medications, its common use, the common problems occured by erroneous medications side effects ...A must to know by duty doctor, registrars and nurses. Most of the presentation slides are in interactive way.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
3. DEFINITION
Wide QRS complex tachycardia is a rhythm with a rate of more than
100 b/m and QRS duration of more than 120 ms
VT (80%)
SVT (20%)
4. VT-
Non-sustained VT: three or more ventricular beats with a maximal
duration of 30 seconds.
Sustained VT: a VT of more than 30 seconds duration (or less if
treated by electrocardioversion within 30 seconds).
Monomorphic VT: all ventricular beats have the same configuration.
Polymorphic VT: the ventricular beats have a changing configuration.
The RR interval is 180-600 ms
Biphasic VT: a ventricular tachycardia with a QRS complex that
alternates from beat to beat.
SVT- a tachycardia dependent on participation of structure at
or above bundle of His
LBBB morphology- QRS > 12 msec. with prominent negative
deflection in V1
RBBB morphology- QRS > 12 msec. with prominent positive
deflection in V1.
5. POINTS IN HISTORY DIAGNOSIS
H/O MI VT
H/O CHF VT
H/O ANGINA VT
Recurrent episodes SVT
Duration of illness >3 years SVT
Minimally symptomatic events including
palpitations and light headedness without
syncope
SVT
Each has a
PPV of 95%
6. PHYSICAL EXAMINATION
Signs of AV dissociation favours VT
- varying intensity of S1
- variation of systolic BP
- hypotension
Termination of WCT with maneuvers ~
carotid,vasalva,adenosine favours SVT
8. OTHER ECG FINDINGS FAVOUR VT
North - west QRS axis deviation i.e superior and rightward
minus 90 degree to 180 degree
Negative or positive concordance of QRS complex in all
precordial leads
AV dissociaton : Fusion beats, capture beats
In LBBB, QRS duration >160 ms
In RBBB,QRS duration > 140 ms
Previous ECG show MI
11. FUSION & CAPTURE BEATS
ECG strip shows series of ectopic beats (a run of Vtach; the ectopic rhythm)
followed by capture beats (normal configuration; the sinus rhythm) and then a
gradual merging of the capture beats into the ectopic beats.
12. New aVR algorithm
Vereckei et al;Heart Rhythm 2008
483 WCT (351 VT, 112 SVT, 20 preexcited tachycardia)
analysed
Greater sensitivity for VT diagnosis than Brugada
algorithm(96.5% vs 89.2%, P .001)
Greater specificity for diagnosing SVT compared with Brugad
criteria
András Vereckei, MD et al Heart Rhythm, Vol 5, No 1, January 2008
14. If the distance traveled on the Y axis in the initial
40ms of the QRS complex is smaller than that
traveled in the terminal 40ms of the QRS complex, a
VT is much more likely
15. ULTRASIMPLE BRUGADA CRITERION: RW TO PEAK
TIME (RWPT)
In 2010 Joseph Brugada et al. published a new
criterion to differentiate VT from SVT in wide
complex tachycardias: the R wave peak time in
Lead II [4].
They suggest measuring the duration of onset of
the QRS to the first change in polarity (either nadir
Q or peak R) in lead II. If the RWPT is ≥ 50ms the
likelihood of a VT very high (positive likelihood ratio
34.8).
16.
17. VT IN STRUCTURALLY NORMAL HEART:
Idiopathic Ventricular tachycardia
10% patients with VT
Structural heart disease can be ruled out if - ECG,
ECHO and CAG are normal
However , MRI can detect RVOT origin VT despite all
modalities being normal
SPECT – single photon emission CT
18. IDIOPATHIC VT
Subclassified based on several criterias: mechanism,
location, response to therapy
OUTFLOW TRACT TACHYCARDIAS
IDIOPATHIC LEFT VTs (ILVT)
AUTOMATIC VTs
19. RVOT VT (80-90% of VT)
ILVT (idiopathic LV outflow tract)
IPVT (idiopathic propranolol sensitive VT)
CPVT (catecholaminergic polymorphic VT)
Brugada Syndrome
Long QT syndrome
VT IN STRUCTURALLY NORMAL HEART:
Inherited Ion-channelopathies
Taken from Supplement of JAPI , 2007
20. OUTFLOW TRACT TACHYCARDIA
Account for most cases (80-90%)
Outflow tract encompases RV region between pulm &
tricuspid valves; AND basal left ventricle (including
LVOT, aortic cusps)
Most commonly presenting as VPCs, Monomorphic
nonsustained VT
Sustained VT less common
Ppt: Exercise, emotional stress, exercise testing,
menstrual cycles in female
21. DAD mediated triggered activity
Typically mediated by intracellular calcium overload
through increased intracellular cAMP
This explains Sensitivity to beta-blockers, CCBs
MECHANISM
Lerman et al, Circulation 1995, 92
22. RVOT VT:
RV monomorphic extrasystoles are considered benign
This may progress to ARVD or RVOT VT, with MRI
evidence of functional/anatomical abnormality
ECG: LBB morphology, inferior Axis, QRS transition in
V3/V4
Common in females of 30-50 yr age
Palpitation, presyncope, syncope (less common)
Exercise or emotional stress
Sudden death is rare
23. Two phenotypic forms:
Non-sustained repetitive monomorphic VT
Paroxysmal exercise induced sustained VT
Classification based on site of origin:
Originating from pulmonary artery
RV-end outflow tract
RVOT VT:
24. LBBB and
inferior axis
Right sided
origin- LBBB
pattern with
transition from
a small r-wave
to a large R-
wave at V3 to
V4
RVOT VT
25. RVOT region can be divided
into nine regions
Anterior sites demonstrate
Q wave (Q or qR) in lead I
and QS in lead aVL
Posterior sites demonstrate
R wave in lead I and early
precordial transition (R> S in
V3)
Between anterior and
posterior locations typically
demonstrate a multiphasic
QRS morphology in lead I
JADONATH AND COLLEAGUES
26. Differentiation of septal
from free wall RVOT VT
RVOT VTs originating from
septum - taller,narrower
monophasic R waves in
inferior leads
Free wall RVOT VT-
typically broader QRS
(>140ms) and R wave
notching in inferior leads
Later transition in
precordial leads (>V4)
DIXIT AND COLLEAGUES
27. Atriofascicular fibers (Mahaim fibers)
AVRT using Rt-sided accessory pathway
VT after repair of TOF
ARVD
DIFFERENTIAL DIAGNOSIS OF RVOT VT
28. ECG during VT
shows
S wave in lead I
R-wave transition
in lead V1or
V2(Earlier precordial
transition zone)
More rightward
axes
Taller R waves in
inferior leads
LVOT VT –
- CLINICALLY SAME LIKE RVOT VT
- MECHANISM ALSO SAME
S wave in LI and R-wave transition in V1 suggest LVOT VT.
R:S amplitude ratio of 30% and R:QRS duration ratio of 50%
Presence of an S wave in leads V5 and V6 suggests an infravalvular
origin of the tachycardia.
29. May originate from supravalvular or
infravalvular endocardial region of
coronary cusp of aortic valve
Distinction is important –RF ablation
LVOT VT
30. RVOT VT Vs aortic cusp VT
R wave duration and R/S wave
amplitude ratio in leads V1
and V2 were greater in
tachycardias originating from
cusp compared with RVOT
Precordial lead transition
earlier in cusp VT occurring
before lead V3
Absence of an S wave in V5 or
V6 -specificity of 88% for cusp
VT compared with RVOT VT
OUYANG AND COLLEAGUES
31. TREATMENT
• Usually benign course
• Good prognosis
1. May respond acutely to carotid sinus massage, Valsalva
maneuvers or intravenous adenosine or verapamil
2. Long-term oral therapy with either BB or CCB
3. Non-responders (33%)- class I or III antiarrhythmic
agents
32. RFA
1. When medical therapy is ineffective or not tolerated
2. High success rate (>80%)
3. Ablation of epicardial or aortic sinuses sites is highly
effective
4. Technically challenging and carries higher risks -
proximity to coronary arteries
5. Recurrence 10%
33. 15 to 40 years
More in men (60%)
Most occur at rest
Usually paroxysmal
Incessant forms
leading to TCM are
described
IDIOPATHIC LEFT VT
35. Baseline 12-lead ECG is normal in most patients
Exit near the area of the left posterior fascicle
RBBB + left superior frontal plane axis
Relatively narrow QRS duration (<140 msec)
RS interval <80 msec
Exit near the area of the left anterior fascicle
RBBB+ right frontal plane axis
36. Long-term prognosis is very good
Patients who have incessant tachycardia may develop a
tachycardia related cardiomyopathy
Intravenous verapamil is effective in acutely terminating VT
Mild to moderate symptoms oral –verapamil
BB and class I and III antiarrhythmic agents useful in some
Medical therapy is often ineffective in patients who have
severe symptoms
37. RFA
Associated with significant symptoms or who are intolerant
or resistant to medical therapy
Post ablation: 10% chances of recurrence (either ILVT or
RVOT-VT) of different morphology
Requires re-ablation
38. AUTOMATIC VENTRICULAR TACHYCARDIA
IPVT: PROPRANOLOL SENSITIVE
A form of IVLT
<50 yr, often ppt by exercise
Can arise from anywhere within heart
Unresponsive to Verapamil
Beta blockers very effective in terminating VT
Chances of SCD
ICD recommended in survivors
39. AHA/ESC GUIDELINES RECOMMENDATIONS
FOR TREATMENT:
Class IC: catheter ablation useful in drug refractory
and symptomatic pts or in pts who are intolerant to
longterm drug therapy
Class IIa:
1. EP study reasonable for diagnosis in suspected outflow tract VT
(LOA: B)
2. BB/CCB can be useful for symptomatic VT arising from RVOT
(LOA: C)
3. ICD – can be effective therapy for sustained VT who are
receiving chronic drug therapy & who have reasonable
expected survival for more than 1yr (LOA:C)
40. LIFE-THREATENING
(TYPICALLY POLYMORPHIC VT)
• Rare
• Generally occurs with genetic ion channel disorders
• Unlike monomorphic VT, associated with SCD
• Abnormalities exist at molecular level
42. LONG QT SYNDROME
Corrected QT interval 440 ms in men and 460 ms in women
with or without morphological abnormalities of the T waves
Decrease in outward potassium currents or increase in
inward sodium currents
Prolongs repolarization phase of cardiac action potential
Result in prolongation of QT interval
Predisposition to torsade de pointes VT
43. Seven types, based on different genes involved
LQT1, LQT2, and LQT3 account for 90%
LQT1 and LQT2 -mutations of KCNQ1 and KCNH2 genes that
encode subunits of IKs and Ikr potassium channels,
respectively
LQT3 -mutations of SCN5A gene that encode subunits of INa
sodium channels
Approximately 25% not have identifiable gene mutations
44. • Mean age of symptom onset is 12 years
• Present with syncope, seizures, or cardiac arrest.
• Clinical presentation and ECG repolarization (ST-T) patterns
have been correlated to genotype
LQT1 -often have broad-based T waves and frequently experience
events during physical activity (especially swimming).
LQT2- T-wave is often notched in multiple leads.
Triggers for LQT2 include startling auditory stimuli (e.g., from an
alarm clock) and emotional upset.
LQT3- often demonstrate long ST segments
Most LQT3 events occur at rest or sleep.
45.
46. MANAGEMENT
1. Avoid trigger events and medications prolong QT interval
2. Risk stratification schemes based on degree of QT prolongation,
genotype, and sex
3. Corrected QT interval exceeding 500 ms poses a high risk for
cardiac events
4. Patients who have LQT2 and LQT3 may be at higher risk for SCD
compared with patients who have LQT1
47. TREATMENT
1. BB are indicated for all patients with syncope and for asymptomatic
patients with significant QT prolongation (IB)
2. Role of BB in asymptomatic patients with normal or mildly prolonged
QT intervals remains uncertain.
3. BB are highly effective in LQT1, but less effective in other LQTS
4. Role of BBs in LQT3 is not established.
5. Because LQT3 is a minority of all LQTS,symptomatic patients who
have not undergone genotyping should receive BBs
48. • ICD are indicated for secondary prevention of cardiac arrest and for
patients with recurrent syncope despite BB therapy
• Less defined therapies
• Gene-specific therapy with mexiletine , flecainide , or ranolazine for
some LQT3 patients
• PPI for bradycardia
• Surgical left cardiac sympathetic denervation for recurrent
arrhythmias resistant to BB therapy (class IIb, LOA-B)
• Catheter ablation of triggering PVCs-abolish recurrent VT/VF
49. BRUGADA SYNDROME
• Characterized by coving ST-segment elevation in V1 to V3
• 2 mm in 2 of these 3 leads are diagnostic
• Complete or incomplete RBBB pattern
• Pattern can be spontaneously present or provoked by sodium-
channel– blocking agents such as ajmaline,flecainide, or
procainamide
• Typical ECG pattern can be transient and may only be detected
during long-term ECG monitoring.
50. CLINICAL PRESENTATION
• Syncope or cardiac arrest
• Predominantly in men in third and fourth decade
• Also been linked to SCD in young men in Southeast Asia and has
several local names,including Lai Tai (“died during sleep”) in Thailand
• Prone to atrial fibrillation and sinus node dysfunction
51. TREATMENT
• No well-validated preventive medical therapy
• Patients who don’t have cardiac arrest risk stratified on the basis of
spontaneous ECG pattern and syncope
• Lowdose quinidine may be used to treat frequent VAs in patients who
already have an ICD (Class IC)
• Quinidine and isoproterenol may be useful in patients having VT storms
• Catheter ablation of triggering PVCs and ablation of RV outflow
epicardial musculature successful in abolishing recurrent VT/VF in a
small number of patients
52. ROLE OF ICD
• ICD are effective in preventing SCD and are indicated for cardiac
arrest survivors (Class IC)
• Major management dilemma arises in decision to place
prophylactically an ICD based on patient’s perceived risk of SCD
53. 1. Patients with spontaneous ECG pattern and syncope are at high risk
and ICD insertion is generally recommended for primary prophylaxis
2. Asymptomatic patients with spontaneous ECG pattern are at
intermediate risk, and their best therapeutic options may need to be
individualized (class IIC)
3. Asymptomatic patients without spontaneous ECG pattern are at low
risk and may be followed up clinically
4. Family history of SCD and specific genotypes do not predict events
54. Disorder of myocardial
calcium homeostasis
Clinically manifested as
exertional syncope and
SCD due to exercise
induced VT
Often polymorphic or
bidirectional
CATECHOLAMINERGIC PMVT.
55. • Autosomal dominant form involves mutation of cardiac ryanodine
receptor (RyR2 gene) in approximately 50% of patients
• Autosomal recessive form, accounting for only 3% to 5% of
genotyped cases-mutations of calsequestrin 2 gene (CASQ2)
• RyR2 and CASQ2 mutations cause intracellular calcium
overload and DAD -basis of arrhythmogenesis
56. • Resting ECG is unremarkable
• Typical VT patterns are reproducible with exercise or catecholamine
infusion
• VAs typically appear during sinus tachycardia rates of 120
beats/min to 130 beats/min, with progressive frequency of PVCs
followed by bursts of bidirectional VT
• Mean age for presentation with syncope is 7.8 - 4 years
• Electrophysiology study is not helpful in risk stratification
57. • Mainstay of medical management is BB therapy
• 46% may have recurrent events while receiving therapy
• CCB may have limited effectiveness as adjunctive therapy
• Flecainide blocks RyR2 receptor and shows promise as a medical
therapy
58. • ICD insertion is appropriate for patients who had cardiac arrest and
with life-threatening VA despite maximal medical therapy
• Recurrent ICD shocks may occur and an initial shock with its
accompanying pain and anxiety may trigger further VAs
• Surgical left cardiac sympathetic denervation -resistant cases